Skip to main content

Table 1 Clinical characteristics of head and neck cancer patients

From: M6P/IGF2Rloss of heterozygosity in head and neck cancer associated with poor patient prognosis

Characteristics Mutated M6P/IGF2R(n = 30) Non Mutated M6P/IGF2R(n = 26) Informative Patients (n = 56) Excluded Patients(n = 83)
Gender (No.) Male: 25 (83%) Male: 23 (89%) Male: 48 (86%) Male: 66 (80%)
p = 0.71; p = 0.42 Female: 5 (17%) Female: 3 (11%) Female: 8 (14%) Female: 17 (20%)
Age (Years) Median: 60.4 Median: 60.9 Median: 61 Median: 60
p = 1.0; p = 0.5 Range: 37–71 Range: 39 – 74 Range: 37 – 74 Range: 30 – 75
Race (No.) White: 25 (83%) White: 17 (65%) White: 42 (75%) White: 52 (63%)
p = 0.2; p = 0.3 Black: 5 (17%) Black: 8 (31%) Black: 13 (23%) Black: 30 (36%)
   Native American: 1 (4%) Native American: 1 (2%) Native American: 1 (1%)
Smoking History Yes: 30 (100%) Yes: 23 (89%) Yes: 53 (95%) Yes: 76 (92%)
p = 0.1; p = 0.5 No: 0 (0%) No: 3 (11%) No: 3 (5%) No: 7 (8%)
Baseline Hgb (g/dL) Median: 14.2 Median: 14 Median: 14.2 Median: 13.5
p = 0.8; p = 0.06 Range: 11.5 – 17 Range: 9.9 – 16.9 Range: 9.9 – 17.3 Range: 10.8 – 25
Karnofsky Performance Median: 90 Median: 90 Median: 90 Median: 90
Status p = 0.9; p = 0.2 Range: 60–100 Range: 70 – 100 Range: 60 – 100 Range: 60 – 100
Tumor Resectability Yes: 18 (60%) Yes: 14 (53%) Yes: 32 (57%) Yes: 49 (59%)
p = 0.8; p = 0.5 No: 12 (40%) No: 12 (47%) No: 24 (43%) No: 34 (41%)
Follow-up (Months) Median: 29 Median: 52 Median: 38.6 Median: 28.2
  Range: 2 – 100 Range: 3–124 Range: 2 – 125 Range: 2 – 97
Treatment (No.)     
p = 0.8; p = 0.8     
RT alone 17 (57%) 16 (61%) 33 (59%) 46 (55%)
RT + Chemotherapy 13 (43%) 10 (39%) 23 (41%) 37 (45%)
Tumor Stage (No.)     
p = 0.4; p = 0.3     
T1 0 0 0 1 (1%)
T2 3 (10%) 6 (23%) 9 (16%) 6 (8%)
T3 14 (47%) 11 (42%) 25 (45%) 45 (54%)
T4 13 (43%) 9 (35%) 22 (39%) 30 (36%)
Tx 0 0 0 1 (1%)
Nodal Stage (No.)     
p = 0.6; p = 0.2     
N0 9 (30%) 8 (31%) 17 (30%) 24 (29%)
N1 7 (23%) 3 (12%) 10 (18%) 15 (18%)
N2 12 (40%) 14 (53%) 26 (46%) 30 (36%)
N3 2 (7%) 1 (4%) 3 (5%) 14 (17%)
Overall Staging (No.)     
p = 0.4; p = 0.08     
II 0 2 (8%) 2 (4%) 0
III 11 (37%) 7 (27%) 18 (32%) 24 (29%)
IVa 17 (57%) 16 (61%) 33 (59%) 45 (54%)
IVb 2 (7%) 1 (4%) 3 (5%) 14 (17%)
Primary Tumor Site (No.)     
p = 0.1; p = 0.07     
Base of tongue 7 (23%) 10 (38%) 17 (30%) 15 (18%)
Tonsil 7 (23%) 4 (16%) 11 (20%) 23 (27%)
Larynx 9 (30%) 3 (11%) 12 (21%) 11 (13%)
Hypopharynx 3 (10) 6 (23%) 9 (16%) 17 (21%)
Paranasal Sinuses 0 2 (8%) 2 (4%) 5 (6%)
Oral Cavity 4 (14%) 1 (4%) 5 (9%) 3 (4%)
Nasopharynx 0 0 0 8 (10%)
Unknown 0 0 0 1 (1%)
  1. 1p-value for comparison between patients with M6P/IGF2R mutated and non mutated tumors. 2p-value for comparison between the M6P/IGF2R informative patients and excluded patients.